| Study Period | 2019 - 2032 |
| Market Size in 2025 | USD 210.0 Million |
| Market Size in 2026 | USD 236.5 Million |
| Market Size by 2032 | USD 505.5 Million |
| Projected CAGR | 13.4% |
| Largest Emirate | Dubai |
| Fastest-Growing Emirate | Abu Dhabi |
| Market Structure | Consolidated |
Explore the market potential with our data-driven report
The UAE genomics market size will be an estimated USD 210.0 million for 2025, and it will grow by 13.4% during 2026–2032, to reach USD 505.5 million by 2032.
The market growth is primarily attributed to the country’s strategic focus on becoming a regional hub for advanced healthcare, personalized medicine, and genomic research, along with significant investments in healthcare infrastructure and biotechnology. The UAE has positioned itself at the forefront of genomic innovation through the landmark Emirati Genome Program, which has already collected genetic data from over 700,000 citizens as of 2025, making it one of the largest population-based genomic initiatives globally.
This ambitious program, operating under the National Genome Strategy, aims to sequence the genomes of all Emirati citizens, creating an unparalleled genetic database that enables precision medicine at a population scale. The country is witnessing an increasing adoption of next-generation sequencing technologies and advanced bioinformatics platforms, strengthening service capabilities and expanding diagnostic and research offerings.
The products category holds the largest market share, of 75%, in 2025, because consumables and reagents, such as sequencing kits, PCR reagents, microarray chips, and sample collection kits, are used repeatedly across hospitals, diagnostic laboratories, and research institutions, generating steady. Instruments also contribute to sales, but their one-time or less frequent purchase makes them secondary.
The services category will have the highest CAGR, of 13.7%, due to growing demand for NGS-based sequencing, computational analysis, and biomarker translation services, supported by government initiatives like the Emirati Genome Program. Additionally, increasing adoption of AI-driven bioinformatics platforms and cloud-based genomics solutions is accelerating the expansion of service offerings, enabling faster data interpretation and more personalized healthcare solutions across the UAE.
The offerings analyzed in this report are:
The sequencing category holds the largest market share, of 45%, in 2025, driven by the widespread adoption of next-generation sequencing (NGS) for diagnostics, research, and personalized medicine applications, supported by government programs. Advanced sequencing capabilities deployed by M42's Omics Center of Excellence and partner facilities enable comprehensive genomic profiling supporting applications from rare disease diagnosis to pharmacogenomic testing.
The gene editing category will have the highest CAGR during the forecast period, due to the growing interest in CRISPR and related gene-editing tools for research, therapeutic development, and agriculture, coupled with government-backed research initiatives. Furthermore, increasing collaborations between UAE research institutions and international genomics centers are accelerating the development and adoption of gene-editing technologies across clinical and agricultural applications.
The technologies analyzed in this report are:
The diagnostics category holds the largest market share, of 40%, in 2025, driven by the government’s focus on preventive healthcare and early disease detection through initiatives like the Emirati Genome Program, which supports widespread genetic testing and screening programs. The demand for reliable diagnostic solutions, particularly for hereditary and chronic diseases, continues to be a key revenue driver.
The precision medicine category will have the highest CAGR, of 13.5%, driven by the rising investments in personalized healthcare, pharmacogenomics, and targeted therapies, combined with government-backed research funding and national health strategies. Additionally, integration of AI and bioinformatics in genomic analysis is enabling more tailored treatment approaches, boosting the growth of precision medicine services across the UAE.
The applications analyzed in this report are:
The pharmaceutical & biotechnology companies category holds the largest market share in 2025. Investment incentives, strategic collaborations with local authorities, and access to national genomics programs enable these companies to expand capabilities in sequencing, bioinformatics, and diagnostic development, supporting innovation in therapeutics and clinical research.
The hospitals & clinics category will have the highest CAGR during the forecast period, driven by the rapid integration of genomic medicine into clinical care pathways. The expansion from specialized academic medical centers to broader hospital networks reflects genomics' transition from research tool to essential diagnostic and treatment planning capability.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
Dubai holds the largest market share, of 45%, in 2025, as the Dubai Science Park hosts numerous genomics companies and research facilities, creating a concentrated ecosystem for industry growth. The emirate's adoption of AI-powered genomic applications and establishment of comprehensive genetic testing infrastructure across both public and private healthcare sectors drives its market lead.
The emirate's genomics market benefits from its diverse, cosmopolitan population providing unique genetic diversity for research applications. Major private hospital groups, including Mediclinic, Aster DM Healthcare, and NMC Healthcare, have established advanced genomic testing capabilities, while initiatives like the Mohammed Bin Rashid University of Medicine and Health Sciences' COVID-19 genome sequencing in 2020 demonstrate research excellence.
Abu Dhabi will have the highest CAGR, of 13.6%, driven by unprecedented government investment and establishment of world-class genomic infrastructure. The city’s diverse expatriate population, rising healthcare expenditure, and strategic focus on digital health solutions are driving demand for advanced diagnostics, personalized medicine, and computational genomics platforms. The emirate hosts the Emirati Genome Program's headquarters and primary facilities, including M42's sequencing centers and biobanks. The Department of Health–Abu Dhabi's regulatory frameworks and innovation initiatives, combined with the presence of leading institutions like the Cleveland Clinic Abu Dhabi and G42 Healthcare, position Abu Dhabi as the UAE's genomics research and development powerhouse.
The emirate's significant market share in 2025 reflects concentrated public sector investment, with initiatives like the Abu Dhabi Bioventure Hub and partnerships between MBZUAI and international research institutions advancing AI applications in genomics. The mandatory genetic testing requirements implemented across Abu Dhabi's 22 primary healthcare centers for premarital screening create consistent service demand. Integration of genomic data with Malaffi, the emirate's unified health information exchange, enables population-scale precision medicine applications that serve as models for global implementation.
The emirates of the market are as follows:
The market is consolidated, reflecting the capital-intensive nature of genomic technologies and importance of established expertise in this specialized field. This concentration enables rapid technology transfer, ensures quality standards alignment with international best practices, and facilitates the scale necessary for population-level genomic initiatives. The market structure encourages collaboration rather than pure competition, with many players participating in consortium approaches to large-scale initiatives like the National Genome Strategy implementation. The establishment of dedicated genomics research centers, including Cleveland Clinic's cardiovascular genomics initiative and M42's clinical AI developments, indicates market maturation beyond service delivery toward innovation leadership.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages